Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

414 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.
Hoster E, Delfau-Larue MH, Macintyre E, Jiang L, Stilgenbauer S, Vehling-Kaiser U, Salles G, Thieblemont C, Tilly H, Wirths S, Feugier P, Hübel K, Schmidt C, Ribrag V, Kluin-Nelemans JC, Dreyling M, Pott C; European MCL MRD Working Group and the European MCL Network. Hoster E, et al. Among authors: macintyre e. J Clin Oncol. 2024 Feb 10;42(5):538-549. doi: 10.1200/JCO.23.00899. Epub 2023 Nov 22. J Clin Oncol. 2024. PMID: 37992261
The European Hematology Association Roadmap for European Hematology Research: a consensus document.
Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research. Engert A, et al. Haematologica. 2016 Feb;101(2):115-208. doi: 10.3324/haematol.2015.136739. Epub 2016 Jan 27. Haematologica. 2016. PMID: 26819058 Free PMC article.
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.
Sarkozy C, Callanan M, Thieblemont C, Obéric L, Burroni B, Bouabdallah K, Damaj G, Tessoulin B, Ribrag V, Houot R, Morschhauser F, Griolet S, Joubert C, Cacheux V, Delwail V, Safar V, Gressin R, Cheminant M, Delfau-Larue MH, Hermine O, Macintyre E, Le Gouill S. Sarkozy C, et al. Among authors: macintyre e. Blood. 2024 Jul 18;144(3):262-271. doi: 10.1182/blood.2024023944. Blood. 2024. PMID: 38669626 Clinical Trial.
A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care.
El-Galaly TC, Gaidzik VI, Gaman MA, Antic D, Okosun J, Copland M, Sexl V, Fielding AK, Doeswijk R, Parker H, Dreyling M, Döhner K, Almeida AM, Macintyre E, Gribben JG, Grønbæk K. El-Galaly TC, et al. Among authors: macintyre e. Hemasphere. 2023 Feb 21;7(3):e842. doi: 10.1097/HS9.0000000000000842. eCollection 2023 Mar. Hemasphere. 2023. PMID: 36844176 Free PMC article. No abstract available.
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.
Kiesewetter B, Dafni U, de Vries EGE, Barriuso J, Curigliano G, González-Calle V, Galotti M, Gyawali B, Huntly BJP, Jäger U, Latino NJ, Malcovati L, Oosting SF, Ossenkoppele G, Piccart M, Raderer M, Scarfò L, Trapani D, Zielinski CC, Wester R, Zygoura P, Macintyre E, Cherny NI; ESMO-MCBS Working Group and Extended Working Group. Kiesewetter B, et al. Among authors: macintyre e. Ann Oncol. 2023 Sep;34(9):734-771. doi: 10.1016/j.annonc.2023.06.002. Epub 2023 Jun 19. Ann Oncol. 2023. PMID: 37343663 Free article.
NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients.
Simonin M, Vasseur L, Lengliné E, Lhermitte L, Cabannes-Hamy A, Balsat M, Schmidt A, Dourthe ME, Touzart A, Graux C, Grardel N, Cayuela JM, Arnoux I, Gandemer V, Huguet F, Ducassou S, Lhéritier V, Chalandon Y, Ifrah N, Dombret H, Macintyre E, Petit A, Rousselot P, Lambert J, Baruchel A, Boissel N, Asnafi V. Simonin M, et al. Among authors: macintyre e. Blood. 2024 Oct 10;144(15):1570-1580. doi: 10.1182/blood.2023023754. Blood. 2024. PMID: 38848537
Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma.
Beishuizen A, Mellgren K, Andrés M, Auperin A, Bacon CM, Bomken S, Burke GAA, Burkhardt B, Brugieres L, Chiang AKS, Damm-Welk C, d'Amore E, Horibe K, Kabickova E, Khanam T, Kontny U, Klapper W, Lamant L, Le Deley MC, Loeffen J, Macintyre E, Mann G, Meyer-Wentrup F, Michgehl U, Minard-Colin V, Mussolin L, Oschlies I, Patte C, Pillon M, Reiter A, Rigaud C, Roncery L, Salaverria I, Simonitsch-Klupp I, Uyttebroeck A, Verdu-Amoros J, Williams D, Woessmann W, Wotherspoon A, Wrobel G, Zimmermann M, Attarbaschi A, Turner SD; European Intergroup for Childhood Non-Hodgkin Lymphoma. Beishuizen A, et al. Among authors: macintyre e. Lancet Haematol. 2023 Mar;10(3):e213-e224. doi: 10.1016/S2352-3026(22)00374-X. Lancet Haematol. 2023. PMID: 36858678 Review.
Impact of T-cell Receptor Status on Mutational Landscape and Outcome in T-ALL.
Dourthe ME, Courtois L, Andrieu GP, Simonin M, Touzart A, Lhermitte L, Petit A, Boissel N, Baruchel A, Asnafi V, Macintyre E. Dourthe ME, et al. Among authors: macintyre e. Hemasphere. 2023 Mar 17;7(4):e871. doi: 10.1097/HS9.0000000000000871. eCollection 2023 Apr. Hemasphere. 2023. PMID: 36950021 Free PMC article. No abstract available.
414 results